Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

NCT03537651
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 13, 2026, 9:59 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

NCT07437105
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-272, Placebo, Tezacaftor, Deutivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

NCT05437120
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 13, 2026, 9:59 PM EDT
Suspended Not applicable Interventional

A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

NCT00005110
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Salmeterol, Albuterol
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Phase 1Phase 2 Interventional

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

NCT06159725
View directory record Official record
Conditions
Persistent Infection, Cystic Fibrosis
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 13, 2026, 9:59 PM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

NCT03447262
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 13, 2026, 9:59 PM EDT
Completed No phase listed Observational

Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis

NCT01343524
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
4 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

NCT02354859
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Gallium nitrate, Normal Saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 13, 2026, 9:59 PM EDT
Terminated Phase 3 Interventional

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

NCT00125346
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin Inhalation Powder
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 21 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Effects of Sildenafil on CFTR-dependent Ion Transport Activity

NCT01132482
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

NCT03482960
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon gas, PFP
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Continuous Cardiorespiratory Monitoring in Cystic Fibrosis

NCT04489186
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Wearable device
Device
Lead sponsor
Byteflies
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

NCT02514473
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, Placebo, VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 13, 2026, 9:59 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

High Resolution Micro OCT Imaging

NCT03256773
View directory record Official record
Conditions
Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 13, 2026, 9:59 PM EDT
Not yet recruiting Not applicable Interventional

Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

NCT07414810
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
micro Sweat Test Patch (mSTP), Sweat Testing using SOC
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
2 Weeks to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 13, 2026, 9:59 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis

NCT04335370
View directory record Official record
Conditions
Cystic Fibrosis, Polymyxin B
Interventions
Blood Draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 13, 2026, 9:59 PM EDT
Recruiting Phase 2 Interventional

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Interventions
BX004, Placebo
Biological · Other
Lead sponsor
BiomX Ltd
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 13, 2026, 9:59 PM EDT
Terminated Phase 4 Interventional

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

NCT05561764
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Bacterial
Interventions
Imipenem/Cilastatin/Relebactam
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Hartford, Connecticut • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function

NCT01494909
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ensure plus
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
10 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 13, 2026, 9:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigating Mucinase Activity in Airway Disease

NCT00596232
View directory record Official record
Conditions
Asthma, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 13, 2026, 9:59 PM EDT
Completed No phase listed Observational

Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients

NCT04994301
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lung T1 MRI
Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 13, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Technology-enabled Patient Support System for Self-management of CF

NCT03910881
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Open-platform patient support system (PSS) app
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 13, 2026, 9:59 PM EDT